Andrew Baum

5 results

Pfizer and Allergan would have to pay the other party just $400 million if either were to pull out of their $160 billion deal due to a change in th(...)

Pfizer is in negotiations with Dublin-based Allergan about buying the group in what would be the biggest ever “tax inversion” — allowing the company to report much lower tax costs by moving its domicile to Ireland. (Photograph: Scott Eisen/Bloomberg)

The chief executive of Allergan, in talks about selling itself to Pfizer to form the world’s largest drugmaker, has cautioned that any attempt by the(...)

AstraZeneca chief executive Pascal Soriot will address a cancer conference in Chicago. Photograph: Luke MacGregor/Reuters

AstraZeneca will this week attempt to show investors why it rejected Pfizer’s near-£70 billion takeover offer as its chief executive flies to the Uni(...)

Novartis says it will develop new business segments in dermatology, heart failure, respiratory illnesses and cell therapy

Pharma firm Novartis plans to buy back $5 billion in stock over two years, and said it would expand in faster-growing areas of healthcare such as trea(...)

AstraZeneca sales in the quarter slid by 6 per cent to $6.25 billion, weighed down by the loss of patent protection on several drugs – including, in some markets, its top-selling cholesterol fighter Crestor – while EPS tumbled 28 per cent.

AstraZeneca has promoted Marc Dunoyer to be its new chief financial officer, plugging a gap in the British drugmaker’s top management team as it grapp(...)